VANDA PHARMACEUTICALS INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
VANDA PHARMACEUTICALS INC. (VNDA) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$174.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$174.00K, a 1438.46% decline year-over-year.
- VANDA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$417.00K, a 234.95% decline year-over-year.
- VANDA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $89.00K.
- VANDA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $144.00K, a 86.05% decline year-over-year.
- VANDA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $555.00K, a 433.65% increase from fiscal 2024.
- VANDA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $104.00K, a 91.06% decline from fiscal 2023.
- VANDA PHARMACEUTICALS INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $1.16M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$174.00K 10-Q · filed 2026-08-06 | -$591.00K 10-Q · filed 2026-08-06 | -$502.00K derived: sum of 3 quarters · filed 2026-08-06 | -$358.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$417.00K 10-Q · filed 2026-08-06 | -$328.00K derived: sum of 2 quarters · filed 2026-08-06 | -$184.00K derived: sum of 3 quarters · filed 2026-08-06 | -$171.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $233.00K derived: sum of 2 quarters · filed 2026-02-12 | $246.00K derived: sum of 3 quarters · filed 2026-08-06 | $555.00K 10-K · filed 2026-02-12 |
| 2025-09-30 | $144.00K 10-Q · filed 2025-10-30 | $157.00K derived: sum of 2 quarters · filed 2026-08-06 | $466.00K 10-Q · filed 2025-10-30 | -$162.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $13.00K 10-Q · filed 2026-08-06 | $322.00K 10-Q · filed 2026-08-06 | -$306.00K derived: sum of 3 quarters · filed 2026-08-06 | $726.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $309.00K 10-Q · filed 2026-08-06 | -$319.00K derived: sum of 2 quarters · filed 2026-08-06 | $713.00K derived: sum of 3 quarters · filed 2026-08-06 | $766.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$628.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $404.00K derived: sum of 2 quarters · filed 2026-02-12 | $457.00K derived: sum of 3 quarters · filed 2026-02-12 | $104.00K 10-K · filed 2026-02-12 |
| 2024-09-30 | $1.03M 10-Q · filed 2025-10-30 | $1.08M derived: sum of 2 quarters · filed 2025-10-30 | $732.00K 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $53.00K 10-Q · filed 2025-10-30 | -$300.00K 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | -$353.00K 10-Q · filed 2025-10-30 | |||
| 2023-12-31 | $1.16M 10-K · filed 2026-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |